Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients

Yun, Sumi; Park, Yujun; Moon, Seyoung; Ahn, Soomin; Lee, Kyoungyul; Park, Hyo Jin; Lee, Hye Seung; Choe, Gheeyoung; Lee, Kyu Sang

doi:10.7150/jca.30573



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2019; 10(13):3070-3078. doi:10.7150/jca.30573 This issue Cite

Research Paper

Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients

Sumi Yun¹, Yujun Park², Seyoung Moon², Soomin Ahn², Kyoungyul Lee³, Hyo Jin Park⁴, Hye Seung Lee², Gheeyoung Choe², Kyu Sang Lee^2✉

1. Department of Diagnostic Pathology, Samkwang Medical Laboratories, Seoul, Republic of Korea
2. Department of Pathology, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea
3. Department of Pathology, Kangwon National University Hospital, Chuncheon-Si, Kangwon-Do, Republic of Korea
4. Department of Pathology, Sheikh Khalifa Specialty Hospital, Ras al Khaimah, United Arab Emirates

Citation:

Yun S, Park Y, Moon S, Ahn S, Lee K, Park HJ, Lee HS, Choe G, Lee KS. Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients. J Cancer 2019; 10(13):3070-3078. doi:10.7150/jca.30573. https://www.jcancer.org/v10p3070.htm

Other styles

Abstract

Programmed death ligand 1 (PD-L1) expression provides significant value to predict prognosis and response following immunotherapy in several types of cancers. However, its clinicopathological and prognostic significance in melanoma remains unclear. PD-L1 and the number of tumor infiltrating lymphocytes (TILs) were investigated in 63 Korean patients with melanoma based on the melanoma scoring system. We also compared the results using the PD-L1 antibodies—22C3 and E1L3N clones. In addition, BRAF gene mutation was detected using anti-BRAF antibody and real-time polymerase chain reaction. Overall, 29 (46.0%), 16 (25.4%), and 18 (28.6%) patients exhibited the acral lentiginous type, nodular type, and other histological subtypes of melanoma, respectively. PD-L1 expression was detected in 37 (58.7%) cases and was closely associated with a CD8+TIL^high phenotype (P < 0.001). Combined survival analysis depending on PD-L1 and CD8+TILs status showed that the PD-L1-/CD8+TIL^high group demonstrated the best survival outcome, whereas patients with PD-L1+/CD8+ TIL^low showed the worst prognosis (P = 0.039). However, PD-L1+/CD8+ TIL^low was not an independent prognostic factor. The 22C3 and E1L3N clones showed a high concordance rate (kappa value, 0.799). BRAF mutation status was not correlated with PD-L1 expression. We suggest that evaluation of the combined status of PD-L1 and TIL might be useful to predict the survival of patients with melanoma.

Keywords: melanoma, prognosis, programmed death ligand 1, tumor infiltrating lymphocytes, 22C3

Citation styles

APA

Yun, S., Park, Y., Moon, S., Ahn, S., Lee, K., Park, H.J., Lee, H.S., Choe, G., Lee, K.S. (2019). Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients. Journal of Cancer, 10(13), 3070-3078. https://doi.org/10.7150/jca.30573.

ACS

Yun, S.; Park, Y.; Moon, S.; Ahn, S.; Lee, K.; Park, H.J.; Lee, H.S.; Choe, G.; Lee, K.S. Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients. J. Cancer 2019, 10 (13), 3070-3078. DOI: 10.7150/jca.30573.

NLM

CSE

Yun S, Park Y, Moon S, Ahn S, Lee K, Park HJ, Lee HS, Choe G, Lee KS. 2019. Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients. J Cancer. 10(13):3070-3078.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.